Form 8-K - Current report:
SEC Accession No. 0001641489-25-000066
Filing Date
2025-12-19
Accepted
2025-12-19 17:10:40
Documents
14
Period of Report
2025-12-19
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vtvt-20251219.htm   iXBRL 8-K 24813
2 EX-3.1 firstamendmenttothesecon.htm EX-3.1 1879
6 GRAPHIC firstamendmenttothesecon001.jpg GRAPHIC 111464
  Complete submission text file 0001641489-25-000066.txt   299284

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vtvt-20251219.xsd EX-101.SCH 1794
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vtvt-20251219_lab.xml EX-101.LAB 22532
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vtvt-20251219_pre.xml EX-101.PRE 13051
17 EXTRACTED XBRL INSTANCE DOCUMENT vtvt-20251219_htm.xml XML 2929
Mailing Address 3980 PREMIER DR SUITE 310 HIGH POINT NC 27265
Business Address 3980 PREMIER DR SUITE 310 HIGH POINT NC 27265 336-841-0300
vTv Therapeutics Inc. (Filer) CIK: 0001641489 (see all company filings)

EIN.: 473916571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37524 | Film No.: 251588489
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)